Free Trial
OTCMKTS:BIOQ

Bioqual Q2 2025 Earnings Results & Report

Bioqual logo
$31.00 0.00 (0.00%)
As of 11/12/2026

Bioqual reported Q2 2025 earnings on January 21, 2025. The company reported EPS of -$1.36.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Bioqual EPS Results

Actual EPS
-$1.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bioqual Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Bioqual Q2 2025 Earnings FAQ

Bioqual (OTCMKTS:BIOQ) reported earnings of -$1.36 per share for Q2 2025. The report was announced on Tuesday, January 21, 2025.

Bioqual Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
BIOQUAL Presents Financial Results for Fiscal Year 2026
See More Bioqual Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bioqual? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bioqual and other key companies, straight to your email.

About Bioqual

Bioqual (OTCMKTS:BIOQ), Inc. is a biomedical research and contract research organization based in the United States. The company provides preclinical research services to pharmaceutical and biotechnology companies, government agencies, and other organizations developing medical treatments, vaccines, and diagnostics.

Its activities include animal-model research, pharmacology, toxicology, infectious-disease studies, and vaccine and therapeutic efficacy testing. Bioqual has experience conducting research involving nonhuman primates and other laboratory animals, supporting the evaluation of potential products before they advance to human clinical trials.

The company’s services are designed to help clients assess safety, effectiveness, and biological responses across a range of medical and public-health applications. Publicly available information about Bioqual’s current leadership, geographic reach, and additional operating details is limited.

View Bioqual Profile